[go: up one dir, main page]

DE602004006009D1 - Pellets mit venlafaxin-hydrochlorid - Google Patents

Pellets mit venlafaxin-hydrochlorid

Info

Publication number
DE602004006009D1
DE602004006009D1 DE602004006009T DE602004006009T DE602004006009D1 DE 602004006009 D1 DE602004006009 D1 DE 602004006009D1 DE 602004006009 T DE602004006009 T DE 602004006009T DE 602004006009 T DE602004006009 T DE 602004006009T DE 602004006009 D1 DE602004006009 D1 DE 602004006009D1
Authority
DE
Germany
Prior art keywords
pellets
weight
hydrochloride
faxine
vena
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004006009T
Other languages
English (en)
Other versions
DE602004006009T2 (de
Inventor
Pal Fekete
Tibor Korbely
Agnes Bozso
Eszter Moricz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Publication of DE602004006009D1 publication Critical patent/DE602004006009D1/de
Application granted granted Critical
Publication of DE602004006009T2 publication Critical patent/DE602004006009T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602004006009T 2003-10-10 2004-10-08 Pellets mit venlafaxin-hydrochlorid Expired - Lifetime DE602004006009T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0303382 2003-10-10
HU0303382A HUP0303382A2 (hu) 2003-10-10 2003-10-10 Venlafaxin-hidroklorid-tartalmú pelletek
PCT/HU2004/000095 WO2005034930A1 (en) 2003-10-10 2004-10-08 Pellets containing venlafaxine hydrochloride

Publications (2)

Publication Number Publication Date
DE602004006009D1 true DE602004006009D1 (de) 2007-05-31
DE602004006009T2 DE602004006009T2 (de) 2008-01-10

Family

ID=90001704

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004006009T Expired - Lifetime DE602004006009T2 (de) 2003-10-10 2004-10-08 Pellets mit venlafaxin-hydrochlorid

Country Status (22)

Country Link
EP (1) EP1677777B1 (de)
CN (1) CN1882321B (de)
AT (1) ATE359771T1 (de)
AU (1) AU2004280132B2 (de)
BG (1) BG109539A (de)
CY (1) CY1106693T1 (de)
CZ (1) CZ2006269A3 (de)
DE (1) DE602004006009T2 (de)
DK (1) DK1677777T3 (de)
EA (1) EA009695B1 (de)
ES (1) ES2285538T3 (de)
HR (2) HRP20060136A2 (de)
HU (1) HUP0303382A2 (de)
IL (1) IL174830A (de)
NO (1) NO20062082L (de)
PL (2) PL379541A1 (de)
PT (1) PT1677777E (de)
RS (2) RS20060252A (de)
SI (1) SI1677777T1 (de)
SK (1) SK50442006A3 (de)
UA (1) UA82268C2 (de)
WO (1) WO2005034930A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101197919B1 (ko) 1999-10-29 2012-11-29 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
EP1906935A4 (de) * 2005-07-28 2010-10-20 Reddys Lab Ltd Dr Venlafaxin-zusammensetzungen mit verlängerter freisetzung
EP2023903B1 (de) * 2006-05-19 2014-04-23 EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság Verfahren für die vorbereitung und oberflächenbeschichtung von tabletten
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20130171256A1 (en) * 2010-05-11 2013-07-04 Cima Labs Inc. Alcohol-resistant extended release dosage forms comprising venlafaxine
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
EA201590776A1 (ru) * 2012-12-19 2015-11-30 Ратиофарм Гмбх Пеллеты с пленочным покрытием
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN114028577B (zh) * 2021-10-20 2024-07-02 珠海市东辰制药有限公司 一种二氧化硅丸芯及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1331003B1 (de) * 1996-03-25 2015-08-26 Wyeth LLC Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
CN1334080A (zh) * 2001-07-25 2002-02-06 成都康弘制药有限公司 盐酸万拉法新缓释片及其制备方法
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations

Also Published As

Publication number Publication date
CY1106693T1 (el) 2012-05-23
CN1882321B (zh) 2011-06-08
IL174830A0 (en) 2008-04-13
PL1677777T3 (pl) 2007-08-31
UA82268C2 (uk) 2008-03-25
HK1098364A1 (en) 2007-07-20
ES2285538T3 (es) 2007-11-16
RS20060252A (sr) 2008-08-07
CZ2006269A3 (cs) 2006-07-12
HRP20060136A2 (en) 2006-06-30
WO2005034930A1 (en) 2005-04-21
DK1677777T3 (da) 2007-09-03
IL174830A (en) 2010-04-15
RS52150B (sr) 2012-08-31
PT1677777E (pt) 2007-06-21
DE602004006009T2 (de) 2008-01-10
SI1677777T1 (sl) 2007-10-31
ATE359771T1 (de) 2007-05-15
HUP0303382D0 (en) 2003-12-29
BG109539A (bg) 2006-11-30
AU2004280132A1 (en) 2005-04-21
HRP20070322T3 (hr) 2007-09-30
EP1677777B1 (de) 2007-04-18
SK50442006A3 (sk) 2006-08-03
EA009695B1 (ru) 2008-02-28
HUP0303382A2 (hu) 2005-08-29
EP1677777A1 (de) 2006-07-12
PL379541A1 (pl) 2006-10-02
NO20062082L (no) 2006-05-09
EA200600675A1 (ru) 2006-08-25
CN1882321A (zh) 2006-12-20
AU2004280132B2 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
DE602004006009D1 (de) Pellets mit venlafaxin-hydrochlorid
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
SG153830A1 (en) Galenic formulations of organic compounds
EA200700388A1 (ru) Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DK1663216T3 (da) Tacrolimus-holdige sammensætninger med modificeret frigivelse
WO2009028495A1 (ja) 真菌性皮膚炎用剤
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
DE60212819D1 (de) Salzformarme polyallylamine
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
WO2003072030A3 (en) Methods for preventing or treating cardiac arrhythmia
IS2393B (is) Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun
DK1711169T3 (da) Coatede mikrodepottabletter med venlafaxinhydrochlorid
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
EA200702496A1 (ru) Местная композиция, содержащая желатин
RU2009145804A (ru) Аксомадол для лечения боли от артроза
SI1589014T1 (sl) Postopek za pripravo derivatov 1,3-dihidro-2h-3-benzazepin-2-ona in uporaba za pripravo ivabradina in farmacevtsko sprejemljivih kislinskih adicijskih soli
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
HUP0303383A2 (hu) Piridazinon-származékot tartalmazó pelletek
UA115684C2 (uk) Фармацевтична композиція для перорального застосування, що містить декскетопрофен та трамадол
RU2006119994A (ru) Противотуберкулезная фармацевтическая композиция
RU2002110957A (ru) Гепатопротекторное средство "Карсилин"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1677777

Country of ref document: EP

Representative=s name: STOLMAR & PARTNER, DE